Population pharmacokinetic analysis of varenicline in adult smokers

200959 citationsJournal Articlebronze Open Access

Authors

Patanjali Ravva · Pfizer (United States)

Marc R. Gastonguay · Metrum Research Group (United States)

Hélène M. Faessel · Pfizer (United Kingdom)

Abstract

Renal function is the clinically important factor leading to interindividual variability in varenicline exposure. A dose reduction to 1 mg day(-1), which is half the recommended dose, is indicated for subjects with severe renal impairment.

Topics & Keywords

Pharmaceutical industry and healthcare Pharmacology and Obesity Treatment Blood Pressure and Hypertension Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Clinical Pharmacology

Volume 68, Issue 5, pp. 669-681

DOI: 10.1111/j.1365-2125.2009.03520.x

Field-Weighted Citation Impact: 6.50